Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms Pembro NEC
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
- 19 Jun 2017 New trial record